GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shukra Pharmaceuticals Ltd (BOM:524632) » Definitions » Cyclically Adjusted Revenue per Share

Shukra Pharmaceuticals (BOM:524632) Cyclically Adjusted Revenue per Share : ₹8.88 (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Shukra Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shukra Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2024 was ₹0.720. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹8.88 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Shukra Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shukra Pharmaceuticals was 18.60% per year. The lowest was 18.60% per year. And the median was 18.60% per year.

As of today (2024-09-21), Shukra Pharmaceuticals's current stock price is ₹62.91. Shukra Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was ₹8.88. Shukra Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 7.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shukra Pharmaceuticals was 14.17. The lowest was 0.36. And the median was 1.58.


Shukra Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Shukra Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shukra Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Shukra Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 5.21 5.36 7.79 8.69

Shukra Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.33 8.73 8.90 8.69 8.88

Competitive Comparison of Shukra Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shukra Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shukra Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Shukra Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shukra Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.72/155.7889*155.7889
=0.720

Current CPI (Jun. 2024) = 155.7889.

Shukra Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.364 96.780 0.586
201412 0.128 96.780 0.206
201503 0.110 97.163 0.176
201506 0.266 99.841 0.415
201509 0.307 101.753 0.470
201512 0.122 102.901 0.185
201603 0.744 102.518 1.131
201606 0.311 105.961 0.457
201609 0.129 105.961 0.190
201612 0.442 105.196 0.655
201703 0.679 105.196 1.006
201706 0.335 107.109 0.487
201709 0.019 109.021 0.027
201712 1.092 109.404 1.555
201803 0.336 109.786 0.477
201806 0.343 111.317 0.480
201809 0.285 115.142 0.386
201812 0.380 115.142 0.514
201903 0.873 118.202 1.151
201906 0.402 120.880 0.518
201909 0.499 123.175 0.631
201912 1.289 126.235 1.591
202003 1.348 124.705 1.684
202006 0.370 127.000 0.454
202009 0.558 130.118 0.668
202012 1.377 130.889 1.639
202103 1.412 131.771 1.669
202106 1.063 134.084 1.235
202109 0.965 135.847 1.107
202112 0.970 138.161 1.094
202203 2.970 138.822 3.333
202206 2.182 142.347 2.388
202209 1.237 144.661 1.332
202212 0.765 145.763 0.818
202303 29.537 146.865 31.332
202306 12.876 150.280 13.348
202309 5.620 151.492 5.779
202312 4.316 152.924 4.397
202403 2.485 153.035 2.530
202406 0.720 155.789 0.720

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Shukra Pharmaceuticals  (BOM:524632) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shukra Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=62.91/8.88
=7.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shukra Pharmaceuticals was 14.17. The lowest was 0.36. And the median was 1.58.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shukra Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Shukra Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shukra Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Judges Bunglow Road, Bodakdev, 3rd Floor, Veer House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments; pharmaceutical and Laboratory. Its product portfolio includes antibiotics, antibiotics, quinolones, macrolides, anti-bacterial, anti-fungal, anti-malarial, anti-viral, antiprotozoal, anti-anthelmintic, anti-depressant, anti-manic, anti-emetic, beta-blockers, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.

Shukra Pharmaceuticals Headlines

No Headlines